Generate Biomedicines seeks a $425 million IPO on NASDAQ, with a price range of $15-$17

LootboxPhobia · 2026-02-24T06:20:26+00:00

Generate Biomedicines has filed for an IPO on NASDAQ, planning to raise up to $425 million by issuing 25 million shares at a price range of $15.00 to $17.00. The company's main candidate product is the anti-asthma antibody GB-0895, which is expected to complete clinical trials by 2028. The company is projected to incur a loss of $223 million in 2025, but partnership revenue has increased.

LootboxPhobia

2026-02-24 06:20:26

Abstract generation in progress

Investing.com - Generate Biomedicines, Inc. has filed to go public on the NASDAQ stock market under the ticker symbol “GENB,” with a maximum offering of up to $425 million. This clinical-stage biopharmaceutical company will issue 25 million common shares, with an estimated price range of $15.00 to $17.00 per share.

The company’s lead candidate, GB-0895, is an investigational long-acting anti-TSL monoclonal antibody for the treatment of severe asthma, administered once every six months. On January 26, 2026, the first patient was dosed in two parallel global Phase 3 clinical trials, which are expected to complete enrollment in the first half of 2028. Generate Biomedicines also received IND approval for two additional candidates, GB-4362 and GB-5267, in December 2025, with dosing of the first patients for these programs expected in 2026.

Generate Biomedicines reported a net loss of $223 million for the fiscal year ending December 31, 2025, compared to a net loss of $181.4 million in 2024. Collaboration revenue increased from $20.5 million in 2024 to $31.9 million in 2025. R&D expenses rose from $175.3 million in 2024 to $224.7 million in 2025.

As of December 31, 2025, the company held $221.5 million in cash, cash equivalents, and marketable securities. Generate Biomedicines has granted underwriters an option to purchase up to an additional 3.75 million shares. Goldman Sachs and Morgan Stanley are serving as lead underwriters, with Piper Sandler, Guggenheim Securities, and Cantor acting as co-managers.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.